Cash flow generation is inconsistent, evidenced by a $50.7 million working capital outflow in 2026Q1 that significantly offset reported net income.
| Cash from Operations | 138.84M | 122.24M | 32.64M | 22.67M | -48.4M | -11.35M | 116.62M | -8.71M | 21.6M |
| Operating CF Margin % | - | 5.02% | 1.61% | 1.2% | -2.71% | -0.68% | 7.8% | -0.63% | 1.72% |
| Operating CF Growth % | 3184.9% | 274.54% | 43.95% | 146.84% | -326.45% | -109.73% | 1438.28% | -140.35% | - |
| Net Income | 261.49M | 225.03M | -10.93M | -134.52M | -662.03M | -117.04M | -57.05M | -76.52M | -47.15M |
| Depreciation & Amortization | 705K | 28.22M | 31.16M | 30.1M | 38.82M | 35.39M | 30.22M | 27.01M | 11.94M |
| Stock-Based Compensation | -11M | 0 | 17.46M | 13.16M | 15.89M | 14.43M | 3.27M | 1.95M | 2.12M |
| Deferred Taxes | -612K | -143.03M | 1.03M | 1.01M | -115K | 1.31M | -6.42M | -919K | -3.63M |
| Other Non-Cash Items | -106.86M | 64.67M | 23.87M | 136.32M | 601.26M | 125.89M | 90.06M | 26.7M | 23.56M |
| Working Capital Changes | -4.9M | -52.66M | -29.97M | -23.4M | -42.22M | -71.33M | 56.54M | 13.06M | 34.76M |
| Change in Receivables | 10.31M | -30.22M | -28.64M | -15.32M | -3.23M | -8.81M | 8.56M | 3.34M | -7.96M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -27.06M | 0 | -13.2M | 15.4M |
| Change in Payables | 8.52M | -6.23M | 6.45M | -13.92M | -3.92M | -11.7M | -6.81M | 19.29M | 21.51M |
| Cash from Investing | -24.51M | -22.3M | -6.32M | -8.79M | -25.29M | -681.83M | -193.54M | -17.82M | -229.55M |
| Capital Expenditures | -2.21M | -7.45M | -6.32M | -6.12M | -12.01M | -15.95M | -15.24M | -16.64M | -19.58M |
| CapEx % of Revenue | 0.09% | 0.31% | 0.31% | 0.32% | 0.67% | 0.95% | 1.02% | 1.2% | 1.56% |
| Acquisitions | 0 | -14.85M | 0 | 0 | -1.55M | -666.91M | -178.31M | -1.19M | -209.97M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -22.3M | 0 | 0 | -2.68M | -11.27M | 0 | 0 | 0 | 0 |
| Cash from Financing | 3.45M | 9.03M | 14.03M | 10.85M | 62.42M | 586.33M | 210.94M | 21.86M | 204.15M |
| Debt Issued (Net) | -655K | -3.76M | -2.36M | -5.73M | 60.15M | 161.59M | 136.69M | 68.94M | 149.73M |
| Equity Issued (Net) | -1.52M | 6.52M | 3.09M | 945K | 4.01M | 477.69M | 50M | 0 | 54.42M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 5.63M | 6.27M | 13.3M | 15.63M | -1.74M | -52.95M | 24.25M | -47.07M | 0 |
| Net Change in Cash | 117.78M | 108.97M | 40.35M | 24.73M | -11.27M | -106.86M | 134.02M | -4.67M | -3.8M |
| Free Cash Flow | 136.63M | 114.79M | 26.32M | 16.56M | -60.41M | -27.3M | 101.38M | -25.35M | 2.02M |
| FCF Margin % | 5.42% | 4.72% | 1.3% | 0.87% | -3.38% | -1.63% | 6.78% | -1.83% | 0.16% |
| FCF Growth % | 377.42% | 336.17% | 58.96% | 127.4% | -121.3% | -126.93% | 499.91% | -1356.87% | - |
| FCF per Share | 0.62 | 0.53 | 0.14 | 0.09 | -0.33 | -0.15 | 0.55 | -0.14 | 0.01 |
| FCF Conversion (FCF/Net Income) | 0.52x | 0.54x | -2.99x | -0.17x | 0.07x | 0.10x | -2.04x | 0.11x | -0.46x |
| Interest Paid | 0 | 0 | 152.51M | 137.85M | 102.53M | 58.96M | 73.05M | 92.81M | 62.77M |
| Taxes Paid | 0 | 0 | 5.71M | 1.14M | 1.59M | 5.28M | 2.17M | 1.55M | 3.15M |
Medicaid reimbursement cycle volatility
As reported in recent financial disclosures, the relationship between net income and operating cash flow is frequently disjointed, with the OCF/NI ratio swinging from a high of 2.36 in 2025Q3 to a negative 1.66 in 2025Q1, indicating significant accrual-based distortions in reported profitability.
The persistent gap between net income and cash generation suggests that reported earnings are heavily influenced by non-cash adjustments and timing differences in revenue recognition. Investors should interpret these fluctuations as a sign that accounting accruals, rather than core operational cash flow, are driving the bottom line in any given quarter.
Based on the company's quarterly cash flow statements, free cash flow trajectory remains erratic, alternating between positive margins and periods of cash burn, such as the negative 2.0% FCF margin observed in 2025Q1, which highlights the difficulty in sustaining consistent cash conversion.
The inability to maintain positive free cash flow across consecutive quarters suggests that the business model is highly sensitive to working capital swings and operational timing. This inconsistency complicates the assessment of the company's long-term ability to self-fund its growth initiatives without relying on external financing.
According to the provided cash flow data, working capital changes are a primary driver of quarterly cash volatility, evidenced by a massive $50.7 million outflow in 2026Q1, which significantly offset the company's reported net income and pressured overall liquidity during the period.
These large, periodic working capital outflows suggest challenges in managing the revenue cycle, likely stemming from the complexity of billing multiple state Medicaid programs. The reliance on government reimbursement creates a structural lag that appears to frequently trap cash in accounts receivable, limiting the company's operational flexibility.
As indicated by the company's historical cash flow filings, capital expenditures remain modest, with CapEx/Revenue ratios consistently hovering below 1% over the last ten quarters, suggesting that the business is not overly burdened by heavy physical asset replacement or infrastructure maintenance requirements.
The low capital intensity reflects the service-oriented nature of the pediatric private duty nursing model, which prioritizes human capital over physical plant investment. While this preserves cash, it also implies that the company's competitive moat is not protected by significant capital barriers, but rather by regulatory and labor-related hurdles.
Quick answers to the most common questions about buying AVAH stock.
Aveanna Healthcare Holdings Inc. (AVAH) generated $122.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Aveanna Healthcare Holdings Inc. (AVAH) generated $114.8M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Aveanna Healthcare Holdings Inc. (AVAH) spent $7.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.